Click here for slides on this topic


Triglyceride (TG)

A lipid molecule composed of three fatty acids combined with glyceriol. Triglycerides are a main storage form of energy in the form of lipid. They occur in many tissues, especially adipose tissue, and they circulate in a variety of lipoprotein particles. Circulating triglyceride concentrations are often elevated in patients with insulin resistance or poorly controlled diabetes.


The following content matched the glossary term: Triglyceride (TG)

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

T195-04

Top

Patient education handout exploring the connection between diabetes and cardiovascular disease.

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

SEQUEL: Longer-Term Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Cardiometabolic Disease

Top

Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308. The SEQUEL study, an extension of the CONQUER study,1 was a double-blind, placebo-controlled study that evaluated the longer-term efficacy and safety of once-daily, controlled-release phentermine plus topiramate, as an adjunct to lifestyle modification, among overweight and obese subjects with cardiometabolic disease.

CONQUER: Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Weight-Related Comorbidities

Top

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352. The CONQUER study was a randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of once-daily, controlled-release phentermine plus topiramate for weight reduction among those who were overweight or obese and had weight-related comorbidities.

BLOOM-DM: Efficacy, Safety of Lorcaserin for Weight Loss Among Those with Type 2 Diabetes

Top

O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-1436. The Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of lorcaserin (administered in conjunction with a lifestyle modification program) for weight loss among those with type 2 diabetes.

Fonseca Commentary

Top

ORIGIN: The Effects of Insulin Glargine and Omega-3 Fatty Acids on Cardiovascular Death in Diabetes or Prediabetes. NDEI.org Education Council Member Vivian A. Fonseca, MD, provides expert commentary on the clinical implications of the ORIGIN omega-3 trial results.

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

1 2 3 Next 

Slide Library Results

Search Results for: Triglyceride (TG) Slides Found: 2
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
Waist Circumference, TG Levels Predict Future MetS in 18- to 19-Yr-Old Females